Please login to the form below

Not currently logged in
Email:
Password:

MyoKardia

This page shows the latest MyoKardia news and features for those working in and with pharma, biotech and healthcare.

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Other partnerships in Sanofi's Sunrise initiative include a $200m cardiomyopathy project with MyoKardia, and funding agreements with start-ups Warp Drive Bio - focusing on the use of genomics to discover

Latest news

  • Sanofi licenses cardiomyopathy programme in $200m deal Sanofi licenses cardiomyopathy programme in $200m deal

    Sanofi licenses cardiomyopathy programme in $200m deal. Has rights to three of MyoKardia’ s programmes. ... MyoKardia's approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2014 Pharma deals during September 2014

    It certainly would have been simpler, but probably more expensive, if Sanofi had acquired MyoKardia! ... That may still be on the cards as Sanofi has made an equity investment in MyoKardia as part of the upfront.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    209. MyoKardia/ Sanofi. Licence and collaboration. 5. Three programmes for treatment of genetic forms of cardiomyopathy.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    MyoKardia appoints COO and medical affairs VP. Dr June Lee and Dr Radhika Tripuraneni join the precision medicines specialist. ... California, US-based MyoKardia has appointed Dr June Lee as chief operating officer and Dr Radhika Tripuraneni as vice

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    Jonathan Fox leaves AstraZeneca for MyoKardia. Will lead programme to target genetic heart disease. ... Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic heart disease. “

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics